Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application ...

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in combination with ...

Results We determined the disturbance of systemic immunity caused by HCC and PDAC, and calculated a peripheral blood immune score (PBIScore) based on the constructed model. The PBIScore exhibited good ...

The symptoms are largely due to the onset of anemia (characterized by the loss of red blood cells) and thrombocytopenia (the ... is a certified oncology nurse that has worked with leukemia and ...

Peripheral T-cell lymphoma (PTCL) is an aggressive tumor derived from mature T cells and natural killer cells with an extremely poor prognosis. Ferroptosis is a mechanism of cell death that is ...

chronic lymphocytic leukemia (CLL), follicular lymphoma, aggressive lymphoma, including diffuse large B-cell lymphoma (DLBCL), renal cell carcinoma, squamous cell carcinoma, cutaneous squamous cell ...

Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Follicular Lymphoma ... anaplastic large cell lymphoma, advanced right-sided colon cancer, ...

Nodal marginal zone lymphoma (NMZL) is a rare type of non-Hodgkin lymphoma (NHL). It belongs to a group of non-Hodgkin lymphomas called marginal zone lymphomas (MZL). There are three types: nodal ...

EDTA-anticoagulated (Sarstedt, Nümbrecht, Germany) or heparinized whole blood was obtained from a healthy donor and from three patients (DLBCL, PMBCL, transformed Follicular Lymphoma ... µl of ...

Background: Primary extranodal marginal zone lymphoma (MZL) of the dura is a rare neoplastic ... the first to present concurrently with CLL/SLL in the bone marrow and peripheral blood investigations.